Research programme: naloxegol/opioid analgesic combination - AstraZeneca/Nektar

Drug Profile

Research programme: naloxegol/opioid analgesic combination - AstraZeneca/Nektar

Alternative Names: Naloxegol/opioid; NKTR-118/opioid - Nektar Therapeutics/AstraZeneca; NKTR-119

Latest Information Update: 13 Jun 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nektar Therapeutics
  • Developer AstraZeneca; Nektar Therapeutics
  • Class Opioid analgesics
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 11 Jun 2014 The Anesthetic and Analgesic Drug Products Advisory Committee of the US FDA schedules a meeting to assess potential cardiovascular risk associated with peripherally-acting opioid receptor antagonists, including naloxegol
  • 14 Jan 2014 Preclinical development of NKTR 119 is ongoing
  • 21 Sep 2009 Preclinical trials in Pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top